NCT00436657View on ClinicalTrials.gov

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Peritoneal NeoplasmsRetroperitoneal NeoplasmsGastrointestinal NeoplasmsAdenocarcinomaNeuroblastomaOvarian NeoplasmsSarcomaAdrenocortical CarcinomaWilms TumorRhabdomyosarcomaDesmoplastic Small Round Cell Tumor
Interventions
DRUG

CHPP of Cisplatin

Starting dose of 100 mg/m\^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.

PROCEDURE

Abdominal Surgery

Surgical removal of abdominal tumors.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00436657 - Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer | Biotech Hunter | Biotech Hunter